



(51) International Patent Classification:
Not classified

(21) International Application Number:
PCT/US2024/034072

(22) International Filing Date:
14 June 2024 (14.06.2024)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/508,169 14 June 2023 (14.06.2023) US

(71) Applicant: **INTERIUS BIOTHERAPEUTICS, INC.**
[US/US]; 3401 Grays Ferry Avenue, Building 200, Suite 300, Philadelphia, Pennsylvania 19146 (US).

(72) Inventors: **BORAL, Debasish**; c/o Interius Biotherapeutics, Inc., 3401 Grays Ferry Avenue, Building 200, Suite 300, Philadelphia, Pennsylvania 19146 (US). **SCHNEPP, Bruce C.**; c/o Interius Biotherapeutics, Inc., 3401 Grays Ferry Avenue, Building 200, Suite 300, Philadelphia, Pennsylvania 19146 (US). **JOHNSON, Philip R.**; c/o Interius

Biotherapeutics, Inc., 3401 Grays Ferry Avenue, Building 200, Suite 300, Philadelphia, Pennsylvania 19146 (US).

(74) Agent: **ZHANG, Clark et al.**; Goodwin Procter LLP, 100 Northern Avenue, Boston, Massachusetts 02210 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,

(54) Title: PSEUDOTYPED VIRAL PARTICLES COMPRISING ENGINEERED CHIMERIC RECEPTOR PROTEINS




FIG. 1A

(57) Abstract: Provided for herein are viral particles comprising a heterologous viral glycoprotein and a targeting moiety, wherein the targeting moiety comprises a polypeptide comprising a formula of T-S₁, wherein T is a target binding domain and S₁ is a stalk portion. As provided for herein, the viral particles further comprises a nucleic acid molecule encoding for a heterologous molecule of interest. As provided for herein, the heterologous molecule of interest may be a tandem CAR. Also provided for herein are compositions comprising the same, and methods of using the same.

[Continued on next page]

SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- *without international search report and to be republished
upon receipt of that report (Rule 48.2(g))*
- *with sequence listing part of description (Rule 5.2(a))*